preclinical related Press Releases
Novavax Announces Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against H1N1 and H5N1
NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains H1N1 Virus-like
Read more...ReNeuron announces positive pre-clinical data with lead stem cell line in peripheral arterial disease
ReNeuron announces positive pre-clinical data with lead stem cell line in peripheral arterial disease 06/04/09 Guildford, UK, 6 April 2009: ReNeuron Group plc (LSE: RENE.L) today announces positive
Read more...Alkermes Presents Positive Preclinical Data on Molecule Designed to Improve Outcomes for Patients Taking Opiod Analgesics
Alkermes Presents Positive Preclinical Data on Novel, Proprietary Molecule Designed to Improve Outcomes for Patients Taking Opioid Analgesics Second New Program Disclosed During Calendar 2008
Read more...Ardea Biosciences's MEK Inhibitor, RDEA119, Demonstrates Synergy with Other Anti-Cancer Agents in Multiple Tumor Types
Ardea Biosciences Presents Preclinical Data on its Lead MEK Inhibitor, RDEA119, Demonstrating Synergy with Other Anti-Cancer Agents in Multiple Tumor Types October 24, 2008--SAN DIEGO--(BUSINESS
Read more...Vaxart Demonstrates Efficacy of Oral Avian Flu Vaccine in Preclinical Studies
PRESS RELEASE: Hollis-Eden Pharmaceuticals Presents HE3235 Update at ASCO Breast Cancer Symposium
PRESS RELEASE: FermaVir Announces Positive Data from Recent Preclinical Studies of FV-100
FermaVir Announces Positive Data from Recent Preclinical Studies of FV-100 FermaVir Pharmaceuticals, Inc. today announced positive results from preclinical studies evaluating FV-100, a highly potent,
Read more...Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
